PSMC5/TRIP1 Antibody

• 产品编号：CST-13392S      品牌：CST       原厂货号：13392S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

PSMC5/TRIP1 抗体识别内源性的PSMC5 (TRIP1)总蛋白。该抗体与19S蛋白酶体调控原件的其他AAA-ATP亚基无交叉反应性。多克隆抗体通过合成与人PSMC5 (TRIP1)蛋白邻近羰基末端的氨基酸序列一致的肽段，免疫动物产生。抗体经蛋白A和肽亲和层析纯化。26S蛋白酶体是一种高丰度，大小约2 MDa的复合物，它具有泛素蛋白酶体途径的蛋白水解臂。它主要由两种亚型复合物组成，19S调节颗粒(RP)和20S催化核心颗粒(CP)，在许多情况下RPs会覆盖CP的任一末端。CP由包含催化位点的2种堆积β-环组成，每一种β-环由7种亚基组成(β_1-7)，且两侧包含两个分别由七个亚基构成的α环 (α_1-7).。因此，20S CP 的结构为α_1-7β_1-7β_1-7α_1-7。RP包括了一个底部和一个盖子。部分底部由ATPases的六角环组成，功能为打开底物蛋白和打开α-亚基交错的N-末端片段的闸门，从而使得未折叠的底物进入催化部位。盖子主要起特异性识别泛素信号的作用(1)。除了19S帽子之外，其他的蛋白和复合物，例如蛋白酶体活化因子28 (PA28/11S)，与20S的筒状末端结合，从而促进闸门的开放和激活。此外，蛋白酶体相关的DUBs和E3s能够改变底物嵌合的多泛素链，这可能调节了它们对降解的敏感性(2)。真核蛋白酶体19S RP包含六个结合不同细胞活性ATP酶(ATPases-associated-with-different-cellular-activities，AAA)蛋白(PSMC1-PSMC6)直接结合到20S CP α环。这些19S RP ATP酶被认为组装成异六聚物孔状结构形式底物转位通道的一部分。AAA-ATP酶水解ATP产生的能量用于底物展开和易位,这是泛素化折叠蛋白降解所必须的，同时需要β亚基形成20S CP的中心小室(3 - 5)。甲状腺激素受体结合蛋白1(PSMC5 TRIP1)是一个19S AAA-ATP酶亚基，参与基因转录的负调控。募集PSMC5至VDR 配体(6)和RARγ2 配体(7)促进其通过蛋白酶体降解。

1. Finley, D. (2009) Annu Rev Biochem 78, 477-513.
2. Lee, M.J. et al. (2011) Mol Cell Proteomics 10, R110.003871.
3. Groll, M. et al. (2000) Nat Struct Biol 7, 1062-7.
4. Braun, B.C. et al. (1999) Nat Cell Biol 1, 221-6.
5. Liu, C.W. et al. (2002) J Biol Chem 277, 26815-20.
6. Masuyama, H. and MacDonald, P.N. (1998) J Cell Biochem 71, 429-40.
7. Giannì, M. et al. (2002) EMBO J 21, 3760-9.

原厂资料：

Homology

Species predicted to react based on 100% sequence homology: D. melanogaster, Zebrafish, Pig

Specificity / Sensitivity

PSMC5/TRIP1 Antibody recognizes endogenous levels of total PSMC5 (TRIP1) protein. This antibody does not cross-react with other AAA-ATPase subunits of the 19S proteasome regulatory particle.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human PSMC5 (TRIP1) protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The 26S proteasome is a highly abundant, ~2 MDa complex that serves as the proteolytic arm of the ubiquitin-proteasome system. It consists largely of two sub-complexes, the 19S regulatory particle (RP) and the 20S catalytic core particle (CP); in many cases two RPs cap either end of a CP. The CP is made of two stacked β-rings that contain the catalytic sites, each of which is made of seven subunits (β_1-7), flanked on either side by two α-rings, which are also made of seven subunits each (α_1-7). Thus, the structure of the 20S CP is α_1-7β_1-7β_1-7α_1-7. The RP includes a base and a lid. The base, in part, is composed of a hexametric ring of ATPases that function to unfold the substrate and open the gate of the interlacing amino-terminal segments of the α-subunits, thus allowing entry of the unfolded substrate into the catalytic chamber. The lid is predominantly involved in specific recognition of the ubiquitin signal (1). In addition to the 19S cap, other proteins and complexes, such as proteasome activator 28 (PA28/11S), bind to the end of the 20S cylinder and activate it by facilitating opening of the gate. Furthermore, proteasome-associated DUBs and E3s can remodel substrate-anchored polyubiquitin chains, which may modulate their susceptibility to degradation (2).The eukaryotic proteasome 19S RP contains six ATPases-associated-with-different-cellular-activities (AAA) proteins (PSMC1-PSMC6) that bind directly to the 20S CP α-ring. These 19S RP ATPases are thought to assemble into a heterohexameric, pore-like structure that forms part of the substrate translocation channel. Energy derived from ATP hydrolysis by the AAA-ATPases is utilized for substrate unfolding and translocation, which is required for degradation of ubiquitinated folded proteins within the central chamber of the 20S CP formed by β-subunits (3-5). Thyroid hormone receptor-interacting protein 1 (PSMC5, TRIP1) is a 19S AAA-ATPase subunit involved in the negative regulation of gene transcription. Recruitment of PSMC5 to liganded VDR (6) and RARγ2 (7) facilitates their degradation via the proteasome.

1. Finley, D. (2009) Annu Rev Biochem 78, 477-513.
2. Lee, M.J. et al. (2011) Mol Cell Proteomics 10, R110.003871.
3. Groll, M. et al. (2000) Nat Struct Biol 7, 1062-7.
4. Braun, B.C. et al. (1999) Nat Cell Biol 1, 221-6.
5. Liu, C.W. et al. (2002) J Biol Chem 277, 26815-20.
6. Masuyama, H. and MacDonald, P.N. (1998) J Cell Biochem 71, 429-40.
7. Giannì, M. et al. (2002) EMBO J 21, 3760-9.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM
NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C.
Do not aliquot the antibody